Can-Fite Reports On New Pre-Clinical Developments With Its NASH Drug Namodenoson; Co. Reports Robust Anti-NASH Effects When Drug Administered Orally, Says Data Supports Selection Of Primary Endpoint For Phase 2 Study
Benzinga Newsdesk